Accès ouvert déclaré 2022 article

Use of a rapid digital microfluidics-powered immunoassay for assessing measles and rubella infection and immunity in outbreak settings in the Democratic Republic of the Congo

Alaine Knipes, Aimee Summers, Alexandros A. Sklavounos, Julian Lamanna, Richard P. S. de Campos, Tanya Narahari, Christopher Dixon, Ryan Fobel, Yassa D. Ndjakani, Léopold Lubula, Alain Nzanzu Magazani, Jean Jacques Muyembe, Yvonne Lay, Elizabeth Pukuta, Diane Waku‐Kouomou, Lijuan Hao, Jolie Kasongo Kayembe, Christian Fobel, Joshua Dahmer, Adam Fraser Lee, Man Ho, Jose Gilberto Camacho Valenzuela, Darius G. Rackus, Roger Shih, Brendon Seale, Ann Chang, Gilson Kipese Paluku, Paul A. Rota, Aaron R. Wheeler, Heather M. Scobie

20Citations signalées, ce qui n’est pas une note de qualité

8Institutions déclarées

3Pays d’affiliation déclarés

Rattachement africain : us, ca, République démocratique du Congo. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

The Democratic Republic of the Congo (DRC) has a high measles incidence despite elimination efforts and has yet to introduce rubella vaccine. We evaluated the performance of a prototype rapid digital microfluidics powered (DMF) enzyme-linked immunoassay (ELISA) assessing measles and rubella infection, by testing for immunoglobulin M (IgM), and immunity from natural infection or vaccine, by testing immunoglobulin G (IgG), in outbreak settings. Field evaluations were conducted during September 2017, in Kinshasa province, DRC. Blood specimens were collected during an outbreak investigation of suspected measles cases and tested for measles and rubella IgM and IgG using the DMF-ELISA in the field. Simultaneously, a household serosurvey for measles and rubella IgG was conducted in a recently confirmed measles outbreak area. DMF-ELISA results were compared with reference ELISA results tested at DRC's National Public Health Laboratory and the US Centers for Disease Control and Prevention. Of 157 suspected measles cases, rubella IgM was detected in 54% while measles IgM was detected in 13%. Measles IgG-positive cases were higher among vaccinated persons (87%) than unvaccinated persons (72%). In the recent measles outbreak area, measles IgG seroprevalence was 93% overall, while rubella seroprevalence was lower for children (77%) than women (98%). Compared with reference ELISA, DMF-ELISA sensitivity and specificity were 82% and 78% for measles IgG; 88% and 89% for measles IgM; 85% and 85% for rubella IgG; and 81% and 83% for rubella IgM, respectively. Rubella infection was detected in more than half of persons meeting the suspected measles case definition during a presumed measles outbreak, suggesting substantial unrecognized rubella incidence, and highlighting the need for rubella vaccine introduction into the national schedule. The performance of the DMF-ELISA suggested that this technology can be used to develop rapid diagnostic tests for measles and rubella.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Use of a rapid digital microfluidics-powered immunoassay for assessing measles and rubella infection and immunity in outbreak settings in the Democratic Republic of the Congo
Date Crossref: 21/12/2022
Éditeur: Public Library of Science (PLoS)
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Centers for Disease Control and Prevention pays non établi dans la notice
Organisme public
Center for Global Health pays non établi dans la notice
Organisme public
University of Toronto Department of Chemistry pays non établi dans la notice
Université ou école supérieure
National Institute for Nanotechnology pays non établi dans la notice
Structure de recherche
Programme National Multisectoriel de Lutte contre le sida République démocratique du Congo (code pays fourni par la source)
Institution
National Institute of Biomedical Research République démocratique du Congo (code pays fourni par la source)
Organisme public
National Center for Immunization and Respiratory Diseases pays non établi dans la notice
Structure de recherche
Ministry of Public Health République démocratique du Congo (code pays fourni par la source)
Organisme public
Division of Global Health Protection pays non établi dans la notice
Institution
Nanotechnology Research Centre pays non établi dans la notice
Structure de recherche
Sci-Bots Inc. pays non établi dans la notice
Entreprise
Field Epidemiology and Laboratory Training Program Kinshasa, République démocratique du Congo (pays nommé en fin d’affiliation)
Structure de recherche

Centers for Disease Control and Prevention, Center for Global Health et Department of Chemistry — University of Toronto, avec 9 autres affiliations. Pays d’affiliation : République démocratique du Congo.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Biosensors and Analytical DetectionVirology and Viral DiseasesMicrofluidic and Bio-sensing Technologies

Lire en accès ouvert Consulter la publication primaire Ouvrir le DOI